Longevity biotech market seen reaching $44.05 billion by 2030

The longevity biotech and epigenetic reprogramming market is projected to grow from $23.93 billion in 2025 to $44.05 billion by 2030, according to The Business Research Company. Rising age-related disease, higher healthcare spending and investment in regenerative medicine are driving demand.

Why it matters: - The longevity biotech and epigenetic reprogramming market is tied to therapies that could extend healthy lifespan and slow age-related decline. - Growing demand for treatments aimed at chronic illnesses such as dementia, diabetes and heart disease is expanding the commercial opportunity. - Rising healthcare spending is helping fund research, clinical trials and commercialization of advanced regenerative therapies.

What happened: - The Business Research Company published a Global Market Report 2026 on the longevity biotech and epigenetic reprogramming market on September 10, 2026. - The market is projected to grow from $23.93 billion in 2025 to $27.11 billion in 2026. - The report forecasts the market will reach $44.05 billion by 2030. - The earlier growth phase implies a 13.3% CAGR from 2025 to 2026. - The longer forecast implies a 12.9% CAGR through 2030.

The details: - Longevity biotech and epigenetic reprogramming aim to target the biological roots of aging at the cellular level. - The technologies reset or alter gene expression patterns without changing DNA sequence. - The approach is designed to rejuvenate aged cells, restore function and delay age-related disease. - The report points to partial epigenetic reprogramming therapies as a key trend. - Other expected trends include senolytic and senomorphic treatments, stem cell-based regenerative approaches, age-disease research and metabolic interventions for healthy aging. - Drivers of growth include demographic aging, regenerative medicine funding, genomic and molecular biology advances, more chronic disease, venture capital and strategic partnerships. - North America was the largest market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspots infographics and updated graphics and tables. - The Business Research Company offers a free sample report at Download a free sample. - The full report is available at View the full report.

Between the lines: - The market forecast reflects a broader shift from treating disease late in life to intervening earlier in the aging process. - The emphasis on personalized anti-aging therapies and gene-editing tools suggests a move toward more targeted and expensive treatments. - The report's regional split suggests established biotech hubs still dominate, while emerging healthcare markets may drive the next wave of growth.

What's next: - Longevity biotech companies will likely keep pushing partial reprogramming, senolytics and stem cell approaches toward clinical validation. - More clinical trials targeting longevity are expected as funding and partnerships deepen. - Asia-Pacific's growth could narrow the gap with North America if investment and healthcare infrastructure continue to expand. - The market's trajectory will depend on whether these therapies show measurable benefits in humans and can scale commercially.

The bottom line: - Longevity biotech is moving from a niche science story to a sizable healthcare market, with rapid growth expected through 2030.